Current and future treatment of chest pain of presumed esophageal origin

Gastroenterology Clinics of North America

Volumn 33, Issue 1, 2004, Pages 93-105

  Schmulson, Max J ^a   Valdovinos, Miguel Angel ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATROPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; CLONAZEPAM; CLONIDINE; DESIPRAMINE; DILTIAZEM; GLYCERYL TRINITRATE; HYOSCYAMINE; IMIPRAMINE; MUSCLE RELAXANT AGENT; NIFEDIPINE; NITRIC ACID DERIVATIVE; NORTRIPTYLINE; PEPPERMINT OIL; PIRENZEPINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DISTRESS SYNDROME; DIZZINESS; ESOPHAGUS ACHALASIA; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MYOTOMY; ESOPHAGUS SPASM; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; HYPERALGESIA; INSOMNIA; META ANALYSIS; NAUSEA; NONCARDIAC CHEST PAIN; REVIEW; SIDE EFFECT; THORAX PAIN; TREMOR;

BEHAVIOR THERAPY; BOTULINUM TOXIN TYPE A; CHEST PAIN; CHOLINERGIC ANTAGONISTS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; MUSCLE RELAXANTS, CENTRAL; NEUROMUSCULAR AGENTS; PSYCHOTROPIC DRUGS;

EID: 1642367164     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(03)00127-4     Document Type: Review

References (64)

1. Achem S.R., Kolts B.E. Current medical therapy for esophageal motility disorders. Am J Med. 92:(Suppl 5A):1992;98S-105S.
2. Bassotti G., Gaburri M., Imbimbo B.P., Betti C., Daniotti S., Pelli M.A., et al. Manometric evaluation of cimetropium bromide activity in patients with nutcracker esophagus. Scand J Gastroenterol. 23:1988;1079-1084.
3. Rao S.S.C., Hayek B., Summers R.W. Functional chest pain of esophageal origin: hyperalgesia or motor dysfunction: esophageal hypersensitivity or motor dysfunction? Am J Gastroenterol. 96:2001;2584-2589.
4. Pimentel M., Bonorris G.G., Chow E.J., Lin H.C. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol. 33:2001;27-31.
5. Bulat R., Fachine E., Chauhan U., Chen Y., Tougas G. Lack of effect of spearmint on lower esophageal sphincter function and acid reflux in healthy volunteers. Aliment Pharmacol Ther. 13:1999;805-812.
6. Orlando R.C., Bozymski E.M. Clinical and manometric effects of nitroglycerine in diffuse esophageal spasm. N Engl J Med. 289:1973;23-25.
7. Swamy N. Esophageal spasm: clinical and manometric responses to nitroglycerine and long acting nitrates. Gastroenterology. 72:1977;23-27.
8. Kikendall J.W., Mellow M.H. Effect of sublingual nitroglycerine and long-acting nitrate preparations on esophageal motility. Gastroenterology. 79:1980;703-706.
9. Richter J.E., Dalton C.B., Buice R.G., Castell D.O. Nifedipine: a potent inhibitor of contractions in the body of human esophagus. Studies in healthy volunteers and patients with nutcracker esophagus. Gastroenterology. 89:1985;549-554.
10. Richter J.E., Spurling T.J., Cordova C.M., Castell D.O. Effects of oral calcium blocker, diltiazem, on esophageal contractions: studies in healthy volunteers and patients with nutcracker esophagus. Dig Dis Sci. 29:1984;649-656.
11. Richter J.E., Dalton C.B., Bradley L.A., Castell D.O. Oral nifedipine in the treatment of non-cardiac chest pain in patients with the nutcracker esophagus. Gastroenterology. 93:1987;21-28.
12. Davies H.A., Lewis M.J., Rhodes J., Henderson A.H. Trial of nifedipina for prevention of esophageal spasm. Digestion. 36:1987;81-83.
13. Cattau E., Castell D., Johnson D.A., Spurling T.J., Hirszel R., Chobanian S.J., et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol. 86:1991;272-276.
14. Simpson L.L. The action of botulinum toxin. Rev Infect Dis. 1:1979;656-659.
15. Pasricha P.J., Ravich W.J., Kalloo A.N. Botulinum toxin for achalasia. Lancet. 341:1993;244-245.
16. Pasricha P.J., Ravich W.J., Hendrix T.R., Sostre S., Jones B., Kalloo A.N. Treatment of achalasia with intrasphincteric injection of botulinum toxin: a pilot trial. Ann Intern Med. 121:1994;590-591.
17. Pasricha P.J., Ravich W.J., Hendrix T.R., Sostre S., Jones B., Kalloo A.N. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med. 322:1995;774-778.
18. Fishman V.M., Parkman H.P., Schiano T.D., Hills C., Dabezies M.A., Cohen S., et al. Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. Am J Gastroenterol. 91:1996;1724-1730.
19. Schiano T.D., Adrain A.L., Cassidy M.J., McCray W., Liu J.B., Baranowski R.J., et al. Use of high resolution endoscopic ultrasonography to assess esophageal wall damage after pneumatic dilation or botulinum toxin injection to treat achalasia. Gastrointest Endosc. 44:1996;151-157.
20. Rollan A., Gonzalez R., Carvajal S., Chianale J. Endoscopic intrasphincteric injection of botulinum toxin for the treatment of achalasia. J Clin Gastroenterol. 20:1995;189-191.
21. Cuilliere C., Ducrotte P., Zerbib F., Metman E.H., de Looze D., Guillemot F., et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut. 4:1997;87-92.
22. Gordon J.M., Eaker E.Y. Prospective study of esophageal botulinum toxin injection in high-risk achalasia patients. Am J Gastroenterol. 92:1997;1812-1817.
23. Bhutani M.S. Gastrointestinal uses of botulinum toxin. Am J Gastroenterol. 92:1997;929-933.
24. Katzka D.A., Castell D.O. Use of botulinum toxin as a diagnostic/therapeutic trial to help clarify an indication for definitive therapy in patients with achalasia. Am J Gastroenterol. 94:1999;637-642.
25. Miller L.S., Parkman H.P., Schiano T.D., Cassidy M.J., Ter R.B., Dabezies M.A., et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci. 41:1996;2025-2031.
26. Miller L.S., Pullela S.V., Parkman H.P., Schiano T.D., Cassidy M.J., Cohen S., et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol. 97:2002;1640-1646.
27. Clouse R.E. Psychopharmacologic approaches to therapy for chest pain of presumed esophageal origin. Am J Med. 27:(Suppl 5A):1992;106S-113S.
28. Clouse R.E., Lustman P.J., Eckert T.C., Ferney D.M., Griffith L.S. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities: a double-blind, placebo-controlled trial. Gastroenterology. 92:1987;1027-1036.
29. Ayd F.J. Jr., Settle E.C. Jr. Trazodone: a novel, broad-spectrum antidepressant. Mod Probl Pharmacopsychiatry. 18:1982;49-69.
30. Cannon R.O. III, Quyyumi A.A., Mincemoyer R., Stine A.M., Gracely R.H., Smith W.B., et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 330:1994;1411-1417.
31. Prakash C., Clouse R.E. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci. 44:1999;2373-2379.
32. Varia I., Logue E., O'Connor C., Newby K., Wagner H.R., Davenport C., et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 140:2000;367-372.
33. Clouse R.E. Psychotropic medications for the treatment of functional gastrointestinal disorders. Clin Perspect Gastroenterol. 2:1999;348-356.
34. Clouse R.E., Prakash C., Anderson R.J., Lustman P. Antidepressants for functional gastrointestinal symptoms and syndromes: a meta-analysis. Gastroenterology. 120:(Suppl 1):2001;A642.
35. Beitman B., Basha I.M., Trombka L.H., Jayaratna M.A., Russell B., Flaker G., et al. Pharmacotherapeutic treatment of panic disorder in patients presenting with chest pain. J Fam Pract. 28:1989;177-180.
36. Wulsin L.R., Maddock R., Beitman B., Dawaher R., Wells V.E. Clonazepan treatment of panic disorder in patients with recurrent chest pain and normal coronary arteries. Int J Psychiatry Med. 29:1999;91-95.
37. Katon W., Hall M.L., Russo J., Cormier L., Hollifield M., Vitaliano P., et al. Chest pain: relationship of psychiatric illness to coronary arteriographic results. Am J Med. 84:1988;1-9.
38. Lantinga L.J., Sprafkin R.P., McCroskery J.H., Baker M.T., Warner R.A., Hill N.E. One-year psychosocial follow-up of patients with chest pain and angiographically normal coronary arteries. Am J Cardiol. 62:1988;209-213.
39. Rey E., Roncero-García E., Alvarez-Sanchez A., Diaz-Rubio M. Long-term outcome of patients with non-cardiac chest pain. Rev Esp Enferm Dig. 94:2002;25-33.
40. Salkovskis P.M. Psychological treatment of noncardiac chest pain: the cognitive approach. Am J Med. 92:(Suppl 5A):1992;114S-121S.
41. Potts S.G., Lewin R., Fox K.A.A., Johnstone E.C. Group psychological treatment for chest pain with normal coronary arteries. Q J Med. 92:1999;81-86.
42. Clum G.A., Clum G.A., Surls R. A meta-analysis of treatments for panic disorder. J Consult Clin Psychol. 61:1993;317-326.
43. Warwick H.M., Clark D.M., Cobb A.M., Salkovskis P.M. A controlled trial of cognitive-behavioural treatment of hypochondriasis. Br J Psychiatry. 169:1996;189-195.
44. Klimes I., Mayou R.A., Pearce M.J., Coles L., Fagg J.R. Psychological treatment for atypical non-cardiac chest pain: a controlled evaluation. Psychol Med. 20:1990;605-611.
45. van Peski-Oosterbaan A.S., Spinhoven P., van Rood Y., van der Does J.W., Bruschke A.V., Rooijmans H.G. Cognitive-behavioral therapy for noncardiac chest pain: a randomized trial. Am J Med. 106:1999;424-429.
46. Eypasch E.P., DeMeester T.R., Klingman R.R., Stein H.J. Physiologic assessment and surgical management of patients with diffuse esophageal spasm. J Thorac Cardiovasc Surg. 104:1992;859-868.
47. Henderson R.D., Ryder D., Maryatt G. Extended esophageal myotomy and short total fundoplication hernia repair in diffuse esophageal spasm: five-year review in 34 patients. Ann Thorac Surg. 43:1987;25-31.
48. Ellis F.H. Esophagomyotomy for noncardiac chest pain resulting from diffuse esophageal spasm and related disorders. Am J Med. 92:(Suppl 5A):1992;129S-131S.
49. Cuschieri A. Endoscopic oesophageal myotomy for specific motility disorders and non-cardiac chest pain. Endosc Surg Allied Technol. 1:1993;280-287.
50. Mayer E.A., Chang L., Lembo T. Brain-gut interactions: implications for newer therapy. Eur J Surg. 582:1998;50-55.
51. Rao S.S.C., Mudipalli R.S., Mujica V., Utech C.L., Zhao X., Conklin J.L. An open-label trial of teophylline for functional chest pain. Dig Dis Sci. 47:2002;2763-2768.
52. Mudipalli R., Utech C., Kempf J., Rao S. A double blind, placebo controlled cross-over study of oral theophylline in functional chest pain. Gastroenterology. 124:(Suppl 1):2003;A122.
53. Delvaux M., Louvel D., Marmet J.P., Campos-Oriola R., Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 12:1998;849-855.
54. Caras S., Krause G., Biesheuvel E., Steinborn C., Weesp B.V. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study. Gastroenterology. 120:(Suppl 1):2001;A217.
55. Kahrilas P.J., Quigley E.M.M., Castell D.O., Spechler S.J. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastroesophageal reflux disease. Aliment Pharmacol Ther. 14:2000;1503-1509.
56. Bradette M., Delvaux M., Staumont G., Fioramonti J., Bueno L., Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci. 39:1994;1171-1178.
57. Johnston B.T., Shils J., Leite L.P., Castell D.O. Effects of octreotide on esophageal visceral perception and cerebral evoked potentials induced by balloon distension. Am J Gastroenterol. 94:1999;65-70.
58. Hazan S., Buckley E., Castell D.O., Achem S.R. Octretide improves sensory and pain thresholds in patients with noncardiac chest pain. Gastroenterology. 110:1996;A132.
59. Delvaux M., Louvel D., Lagier E., Scherrer B., Abitbol J.L., Frexinos J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology. 116:1999;38-45.
60. Okano S., Ikeura Y., Inatomi N. Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J Pharmacol Exp Ther. 300:2002;925-931.
61. McRoberts J.A., Coutinho S.V., Marvizon J.C., Grady E.F., Tognetto M., Sengupta J.N., et al. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology. 120:2001;1737-1748.
62. Plourde V., St-Pierre S., Quirion R. Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. Am J Physiol. 273:1997;G191-G196.
63. Kuiken S.D., Lei A., Tytgat G.N., Holman R., Boeckxstaens G.E. Effect of the low-affinity, noncompetitive N-methyl-d-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. Aliment Pharmacol Ther. 16:2002;1955-1962.
64. Cochrane S.W., Gibson M.S., Myers D.A., Shulkin J., Rice K.C., Gold P.W., et al. Role of corticotropin releasing factor-1 (CRF1) receptor mediated mechanisms in neural pathways modulating colonic hypersensitivity. Gastroenterology. 120:(Suppl 1):2001;A7.